THERAPEUTIC PROGRESS–REVIEW XXVIII: PLATELET FUNCTION AND CALCIUM CHANNEL BLOCKING AGENTS

Platelets play a major role in the pathogenesis of vascular disorders such as coronary heart disease. The control of platelet function centres on the concentration of free intra‐cellular Calcium ions (Ca2+). Increases in intra‐cellular Ca2+ will result in platelet activation and release of substances such as thromboxane A2 which will stimulate further platelet activation and vasoconstriction, leading to vascular damage, thrombosis and ischaemia. Calcium channel blocking agents (CCB's) have the ability to reduce Ca2+ availability and may have potentially beneficial effects on platelet function. CCB's have been convincingly shown to have anti‐platelet properties in vitro. They have also shown anti‐platelet properties in vivo although this finding has not been consistent. In addition they have been shown to act synergistically with other anti‐platelet agents.

[1]  P. Fenster,et al.  Effects of oral diltiazem on platelet function: alone and in combination with "low dose" aspirin. , 1986, Thrombosis Research.

[2]  M. Kendall,et al.  CALCIUM ANTAGONISM—WITH SPECIAL REFERENCE TO DILTIAZEM , 1986, Journal of clinical and hospital pharmacy.

[3]  N. Ardlie,et al.  Collagen increases cytoplasmic free calcium in human platelets. , 1986, Thrombosis research.

[4]  C. Forbes,et al.  Inhibition of whole blood platelet aggregation by nicardipine, and synergism with prostacyclin in-vitro. , 1986, Thrombosis research.

[5]  L. Harker.  Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. , 1986, Circulation.

[6]  H. Wallenburg,et al.  LOW-DOSE ASPIRIN PREVENTS PREGNANCY-INDUCED HYPERTENSION AND PRE-ECLAMPSIA IN ANGIOTENSIN-SENSITIVE PRIMIGRAVIDAE , 1986, The Lancet.

[7]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[8]  C. Forbes,et al.  The low dose aspirin controversy solved at last? , 1985, British medical journal.

[9]  S. Uzan,et al.  PREVENTION OF PRE-ECLAMPSIA BY EARLY ANTIPLATELET THERAPY , 1985, The Lancet.

[10]  M. Kendall,et al.  Are Calcium Antagonists Cardioprotective? , 1985, Journal of the Royal College of Physicians of London.

[11]  J. Zahavi,et al.  Enhanced Platelet Release Reaction, Shortened Platelet Survival Time and Increased Platelet Aggregation and Plasma Thromboxane B2 in Chronic Obstructive Arterial Disease , 1985, Thrombosis and Haemostasis.

[12]  C. Forbes,et al.  ASPIRIN WITH AN ADRENERGIC OR A CALCIUM-CHANNEL-BLOCKING AGENT AS NEW COMBINATION THERAPY FOR ARTERIAL THROMBOSIS , 1985, The Lancet.

[13]  J. Mehta,et al.  Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism. , 1985, The American journal of cardiology.

[14]  Bonnie F. Sloane,et al.  Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors. , 1984, Thrombosis research.

[15]  P. Uotila,et al.  Thromboxane formation during blood clotting is decreased by verapamil. , 1984, Prostaglandins, leukotrienes, and medicine.

[16]  C. Dollery,et al.  Thromboxane and prostacyclin in disease: a review. , 1983, The Quarterly journal of medicine.

[17]  D. Macintyre,et al.  Phospholipid-induced human platelet activation: effects of calcium channel blockers and calcium chelators. , 1983, Thrombosis research.

[18]  N. Ardlie,et al.  Effect of the Calcium-Entry Blocking Agent Nifedipine on Activation of Human Platelets and Comparison with Verapamil , 1983, Thrombosis and Haemostasis.

[19]  E. Myhre,et al.  The effects of nifedipine, a calcium antagonist, on platelet function. , 1983, American heart journal.

[20]  G. Davı̀,et al.  Effects by nifedipine on thromboxane synthesis in vitro and in vivo , 1982 .

[21]  L. Edmunds,et al.  Inhibition of human platelet function by verapamil. , 1982, Thrombosis research.

[22]  Y. Ikeda,et al.  Inhibition of Human Platelet Functions by Verapamil , 1981, Thrombosis and Haemostasis.

[23]  L. Hillis,et al.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.

[24]  B. Vargaftig,et al.  Present concepts on the mechanisms of platelet aggregation. , 1981, Biochemical pharmacology.

[25]  J. Mehta,et al.  Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia. , 1980, Thrombosis research.

[26]  E. Gerber,et al.  Regulation of the intracellular calcium level in human blood platelets: cyclic adenosine 3',5'-monophosphate dependent phosphorylation of a 22,000 dalton component in isolated Ca2+-accumulating vesicles. , 1979, Biochimica et biophysica acta.

[27]  J. Mehta,et al.  Platelet Aggregation in Aortic and Coronary Venous Blood in Patients With and Without Coronary Disease , 1978, Circulation.

[28]  J. Vane,et al.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. , 1977, Prostaglandins.

[29]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.

[30]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[31]  N. Ardlie,et al.  The Influence pH, Temperature, and Calcium on Platelet Aggregation: Maintenance of Environmental pH and Platelet Function for in Vitro Studies in Plasma Stored at 37° C , 1974 .

[32]  N. Ardlie,et al.  The influence of pH, temperature, and calcium on platelet aggregation: maintenance of environmental pH and platelet function for in vitro studies in plasma stored at 37 degrees C. , 1974, British Journal of Haematology.

[33]  P. Steele,et al.  Platelet Function Studies in Coronary Artery Disease , 1973, Circulation.

[34]  P. Steele,et al.  Platelet function in coronary artery disease. , 1971, Journal of Laboratory and Clinical Medicine.

[35]  J. Mustard,et al.  Coagulation Tests and Platelet Economy in Atherosclerotic and Control Subjects , 1962, Circulation.